---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-136715"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:24:54.432727+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verrica Q1 2024: YCANTH revenue $3.2M, net loss $20.3M, cash runway into Q1 2025

## Summary
- YCANTH product revenue of $3.2M; no prior-year comparable as sales began Q3 2023.
- Net loss $20.3M ($0.44/sh) vs $6.6M loss ($0.15/sh) in Q1 2023; non-GAAP loss $17.8M.
- SG&A expense surged to $16.3M from $4.3M due to commercial ramp; R&D $4.9M vs $2.7M.
- Cash and equivalents $48.9M; company expects to fund operations into Q1 2025.
- Received NCE status (5-year exclusivity) and permanent J-Code for YCANTH; Phase 2 data for VP-315 (BCC) expected Q2 2024.

## SEC filing metadata
- accession: 0001193125-24-136715
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312524136715/0001193125-24-136715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312524136715/d805970d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-136715
- JSON: https://secwatch.observer/filing/0001193125-24-136715.json
- Plain text: https://secwatch.observer/filing/0001193125-24-136715.txt

## Key facts
- Earnings Releases
  Verrica Pharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue $3.2 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $3.2 million
  - Result: reported results
  source text: Verrica recognized product revenue of $3.2 million in the first quarter of 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312524136715/0001193125-24-136715-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.